Teplizumab benefits type 1 diabetes patients in midstage study

08/9/2013 | United Press International

Type 1 diabetes patients who were on teplizumab, an experimental treatment, were able to maintain their insulin production rates for two years, longer than patients on most other diabetes medications, according to data from a Phase II study published in Diabetes. However, about half of patients did not benefit from the drug. Researchers said patients who saw the most benefit were those who still had good glucose control and moderate insulin requirements at the start of the study.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR